Stay updated with breaking news from Mohamed Eid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
More than 35 million adults in the U.S. have chronic kidney disease (CKD). However, as many as 90% of them are unaware of their condition. This is despite clinical guidelines, which show that using two tests can help detect it. That's why Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced the ...
The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of ...
Eli Lilly and Company and Boehringer Ingelheim announced the FDA approval of empagliflozin (Jardiance) for chronic kidney disease management on September 22, 2023.
This approval marks the fourth endorsement by the FDA for empagliflozin, all of which have been linked to the EMPOWER program.
The approval comes weeks after the Biden administration announced Jardiance was among the first 10 prescription drugs selected for Medicare price negotiations under the Inflation Reduction Act.